Novo Nordisk's Midyear Reckoning: A Failed Trial, a Legal Offensive, and a Buyback Cushion
Published on 08/04/2026 at 18:24 | Redaktion boerse-global.de
The numbers due Wednesday will tell only part of the story. When Novo Nordisk publishes its first-half results, investors will be parsing far more than revenue and earnings per share — they'll be weighing a clinical setback, a legal salvo at its biggest rival, and the quiet mechanics of a share buyback that has been running in the background all summer.
The stock has been caught in a tug-of-war. After shedding 8.56% last week, the shares have stabilized around the €41 mark, though the recovery looks tentative. On Tuesday, the stock traded at €41.05, up 0.53% on the day, but still down 8.07% on the week. The technical picture reflects that indecision: the shares sit barely above their 50-day moving average of €41.00, while the 14-day RSI of 42.8 points to neither oversold nor overbought conditions. The 200-day average of €40.34 looms as a critical support level — a decisive break below it would darken the chart outlook considerably.
What knocked the shares off course
The immediate trigger for last week's slide came on Friday, July 31, when the Phase 3 ZEUS trial missed its primary endpoint. Ziltivekimab, an IL-6 antibody being tested in patients with atherosclerotic cardiovascular disease and chronic kidney impairment, failed to significantly reduce major adverse cardiovascular events versus placebo. The hazard ratio came in at 0.99 — essentially no effect.
Morningstar analyst Karen Andersen called the outcome disappointing but cautioned against overreacting. Ziltivekimab was never expected to contribute more than a small slice of group revenue before 2035, she noted. Novo Nordisk has maintained its 2026 operating profit guidance, though a non-cash impairment charge will hit the books in the third quarter.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
A counterpunch in the courtroom
Rather than merely downplaying the setback, the Danish group has gone on the offensive. On July 21, Novo Nordisk filed suit against Eli Lilly in the US District Court for the District of New Jersey, alleging misleading advertising for Lilly's obesity medications, including the recently launched Foundayo. The complaint centers on claims that Lilly's marketing compares its highest doses against lower doses of Novo's products, relying on outdated clinical data.
The legal clash underscores how fierce competition in the weight-loss market has become. Industry projections put the segment above the $100 billion mark by the end of the decade, and Novo Nordisk's oral Wegovy — which launched on January 5 — has been a bright spot, surpassing three million prescriptions early in the year. Yet competitive pressure has intensified since spring, and the lawsuit reflects the stakes.
Buyback machinery keeps turning
Amid the noise, the company has quietly continued its share repurchase program. Since launching on February 4, 2026, Novo Nordisk has bought back B-shares worth 7.16 billion Danish kroner out of a total program of 15 billion kroner spread over twelve months. By July 24, the company held just over 43 million B-shares in treasury — roughly one percent of total share capital — providing a technical buffer during a turbulent stretch for the sector.
A leadership milestone
Wednesday's report also lands almost exactly on the first anniversary of Mike Doustdar's tenure. The first non-Danish CEO in the company's century-plus history took the helm on August 7, 2025, pursuing a strategy of "disciplined diversification" aimed at expanding the pipeline beyond the dominant GLP-1 franchise into cardiovascular and kidney disease. The half-year figures will offer the first hard evidence of how far that transformation has progressed in the financials.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
What investors are watching
Consensus estimates for the second quarter point to earnings per share of $0.77 on revenue of roughly $10.89 billion. Beyond the headline numbers, the market will be looking for concrete updates on the Wegovy supply chain and the integration of recent acquisitions. Prescription trends for the oral Wegovy pill will also be scrutinized — sustained growth there could help push the ZEUS disappointment into the background.
The shares still sit about 25% below their 52-week high of €54.86 from late January, and the gap between promise and price has narrowed. Whether Wednesday's report narrows it further — or widens it — depends on how convincingly Novo Nordisk can argue that its pipeline setbacks are manageable and its growth story intact.
Ad
Novo Nordisk Stock: New Analysis - 4 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
